BioXcel Therapeutics Inc (BTAI) Actualités

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq:...

BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq:...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report